20 terminated. 20 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Terminated 20 |
| Phase 2 | 7 | Terminated 7 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) Kamuvudine-9 - Thyroid Eye Disease | Phase 1 | Terminated | Peter Timoney | 4 | 2024-11-06 | 2026-04-01 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors IK-595 - Solid Tumor, Adult, Colorectal Cancer | Phase 1 | Terminated | Ikena Oncology | 75 | 2023-12-18 | 2025-09-19 |
| Intraoperative Parathyroid Gland (PTG) Identification Using a Hand-Held Imager (HHI) Parathyroid auto-fluorescence imaging, Indocyanine green - Thyroid Disease, Thyroid Surgery | Phase 1 | Terminated | OPTOSURGICAL, LLC | 44 | 2023-09-01 | 2026-09-22 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors ABM-1310, Cobimetinib - Advanced Solid Tumor, BRAF V600 Mutation | Phase 1 | Terminated | ABM Therapeutics Corporation | 53 | 2020-06-16 | 2024-05-21 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 41 | 2019-12-06 | 2024-06-13 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors Nanrilkefusp alfa, Pembrolizumab - Thyroid Cancer, Renal Cell Carcinoma | Phase 1 | Terminated | SOTIO Biotech AG | 115 | 2019-06-13 | 2026-03-27 |
| A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. Imatinib Oral Tablet - Papillary Thyroid Cancer | Phase 1 | Terminated | AHS Cancer Control Alberta | 14 | 2018-09-18 | 2025-06-27 |
| Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide - Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 12 | 2018-08-31 | 2026-03-20 |
| QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer ETBX-011, ALT-803 - Thyroid Cancer, Colon Cancer | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 3 | 2017-06-26 | 2024-08-06 |
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Alectinib - ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2017-06-19 | 2021-09-27 |
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors eFT508 - Cancer | Phase 1 / Phase 2 | Terminated | Effector Therapeutics | 66 | 2015-12-03 | 2020-11-02 |
| Safety Study of MGD009 in B7-H3-expressing Tumors MGD009 - Mesothelioma, Bladder Cancer | Phase 1 | Terminated | MacroGenics | 67 | 2015-09-01 | 2022-02-08 |
| Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors CC-90003 - Neoplasm Metastasis | Phase 1 | Terminated | Celgene | 19 | 2015-01-05 | 2019-11-18 |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. PLX8394 - Melanoma, Thyroid Cancer | Phase 1 | Terminated | Fore Biotherapeutics | 5 | 2014-02-01 | 2020-10-19 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 116 | 2012-10-16 | 2026-11-05 |
| A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Bortezomib, Vandetanib - Medullary Thyroid Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 22 | 2009-02-19 | 2018-11-29 |
| Safety Study of CALAA-01 to Treat Solid Tumor Cancers CALAA-01 - Cancer, Solid Tumor | Phase 1 | Terminated | Calando Pharmaceuticals | 24 | 2008-05-01 | 2013-11-01 |
| Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate) - Solid Tumor, Thyroid Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 21 | 2004-12-01 | 2014-12-17 |
Thyroid Neoplasms (15) · Melanoma (11) · Carcinoma, Non-Small-Cell Lung (10) · Ovarian Neoplasms (7) · Breast Neoplasms (6) · Colorectal Neoplasms (5) · Neoplasms (5) · Pancreatic Neoplasms (5) · Carcinoma, Renal Cell (4) · Neoplasm Metastasis (4) · Sarcoma (4) · Carcinoma, Medullary (3) · Cholangiocarcinoma (3) · Colonic Neoplasms (3) · Lung Neoplasms (3)
Endocrine System Diseases (20) · Neoplasms by Site (18) · Neoplasms by Histologic Type (16) · Endocrine Gland Neoplasms (15) · Head and Neck Neoplasms (15) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Nerve Tissue (15) · Neuroectodermal Tumors (15) · Neuroendocrine Tumors (15) · Neoplasms, Glandular and Epithelial (14) · Neoplasms (13) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Carcinoma (12)
Imatinib Mesylate (2) · ALT-803 (1) · Bevacizumab (1) · Bortezomib (1) · CALAA-01 (1) · Capecitabine (1) · Cetuximab (1) · Cyclophosphamide (1) · Dacarbazine (1) · Disulfides (1) · Etoposide (1) · Immunoglobulin G (1) · Indocyanine Green (1) · Interleukin-15 (1) · PLX8394 (1)
M.D. Anderson Cancer Center (3) · ABM Therapeutics Corporation (1) · AHS Cancer Control Alberta (1) · Actym Therapeutics, Inc. (1) · Aminex Therapeutics, Inc. (1) · Calando Pharmaceuticals (1) · Celgene (1) · Dana-Farber Cancer Institute (1) · Effector Therapeutics (1) · Fore Biotherapeutics (1) · Ikena Oncology (1) · MacroGenics (1) · NantCell, Inc. (1) · National Cancer Institute (NCI) (1) · OPTOSURGICAL, LLC (1)
United States (19) · Australia (4) · Canada (2) · Czechia (1) · France (1) · South Korea (1) · Spain (1)
Anthony W Tolcher, M.D. (1) · Antoni Ribas, M.D. (1) · Caroline Germa, MD (1) · Demetrios Petropoulos (1) · Gordon Bray, MD (1) · James Yao, MD (1) · Jennifer Spratlin, MD FRCPC (1) · Jeremy Barton, MD (1) · Kaitlyn Frazier, MD (1) · Mark Awad, MD (1) · Michael Armstrong, MD (1) · Peter Timoney (1) · Ravi A Madan, M.D. (1) · Sarina A Piha-Paul (1)
PMID 20305636, PMID 25086465, PMID 26933802, PMID 30297385, PMID 35340114, PMID 37311055, PMID 37554762, PMID 41389341
2018 (1), P30CA016672 (1)